Please assess the completion status of the following clinical trial:

Trial Title: Hydroxyurea for Children and Young Adults With Sickle Cell Disease and Pulmonary Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 10 and 25 years old~* Sickle cell disease with hemoglobin SS, SC or S-B\^0 thalassemia confirmed on hemoglobin electrophoresis~* Tricuspid regurgitant jet velocity (TRJV) equal to or greater than 2.5 m/sec on 2 baseline Doppler echocardiograms at least 3 months apart~Exclusion Criteria:~* Patients already being treated with hydroxyurea~* Patients on a chronic transfusion protocol~* Patients with evidence of hepatic (alanine aminotransferase \[ALT\] equal to or greater than 2 SD above normal) or renal dysfunction (creatinine \[Cr\] equal to or greater than 2 SD above normal)~* Patients who are pregnant~* Patients with documented causes of severe pulmonary hypertension other than from SCD

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- Hydroxyurea (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).